Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenx SE stock logo
ARGX
argenx
$576.24
-0.6%
$587.69
$359.37
$678.21
$35.19B0.57324,369 shs230,594 shs
BioNTech SE stock logo
BNTX
BioNTech
$97.53
-1.0%
$97.48
$76.53
$131.49
$23.45B1.35914,608 shs510,755 shs
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
$14.59
-0.5%
$14.66
$12.58
$15.43
$46.42B0.261.93 million shs1.39 million shs
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$18.13
+2.4%
$15.47
$12.47
$22.80
$20.56B0.629.99 million shs11.47 million shs
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenx SE stock logo
ARGX
argenx
-0.61%-1.49%-7.20%-7.76%+57.30%
BioNTech SE stock logo
BNTX
BioNTech
-1.04%-1.57%-6.22%-10.36%+3.65%
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
-0.61%+1.85%-3.82%+1.71%+11.25%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
+2.31%+9.38%+20.63%+11.08%+8.14%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
argenx SE stock logo
ARGX
argenx
3.3509 of 5 stars
3.52.00.00.04.21.71.9
BioNTech SE stock logo
BNTX
BioNTech
2.5558 of 5 stars
4.42.00.00.03.10.80.0
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
3.5034 of 5 stars
0.05.02.50.03.50.02.5
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
3.1347 of 5 stars
3.65.00.80.02.70.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenx SE stock logo
ARGX
argenx
3.05
Buy$709.1823.07% Upside
BioNTech SE stock logo
BNTX
BioNTech
2.89
Moderate Buy$141.7345.32% Upside
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
3.00
BuyN/AN/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
3.11
Buy$24.5035.14% Upside

Current Analyst Ratings Breakdown

Latest TEVA, TAK, ARGX, and BNTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$25.00
5/22/2025
BioNTech SE stock logo
BNTX
BioNTech
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$120.00 ➝ $116.00
5/22/2025
BioNTech SE stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$134.00 ➝ $134.00
5/21/2025
argenx SE stock logo
ARGX
argenx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/14/2025
BioNTech SE stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$145.00 ➝ $134.00
5/14/2025
argenx SE stock logo
ARGX
argenx
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$699.00
5/14/2025
argenx SE stock logo
ARGX
argenx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/13/2025
argenx SE stock logo
ARGX
argenx
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
5/13/2025
argenx SE stock logo
ARGX
argenx
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$680.00 ➝ $680.00
5/12/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$21.00 ➝ $23.00
5/9/2025
argenx SE stock logo
ARGX
argenx
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$704.00 ➝ $708.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenx SE stock logo
ARGX
argenx
$2.58B13.64N/AN/A$69.22 per share8.32
BioNTech SE stock logo
BNTX
BioNTech
$2.75B8.54$4.19 per share23.25$92.17 per share1.06
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
$4.58T0.01$3.42 per share4.27$15.39 per share0.95
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$16.62B1.24$3.59 per share5.05$4.75 per share3.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenx SE stock logo
ARGX
argenx
-$295.05M$16.21N/A53.11N/A-2.11%-1.45%-1.29%7/24/2025 (Estimated)
BioNTech SE stock logo
BNTX
BioNTech
$1.01B-$3.40N/AN/AN/A-15.16%-2.35%-2.05%8/4/2025 (Estimated)
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
$994.06M$0.2236.488.840.244.53%9.39%4.53%7/30/2025 (Estimated)
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
-$1.64B-$1.15N/A6.891.44-9.91%42.46%6.65%7/30/2025 (Estimated)

Latest TEVA, TAK, ARGX, and BNTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
argenx SE stock logo
ARGX
argenx
$2.32$2.58+$0.26$2.58$748.34 million$1.35 billion
5/8/2025Q4 2025
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
$0.24$0.16-$0.08-$0.21$8.02 billion$7.34 billion
5/7/2025Q1 2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$0.47$0.52+$0.05$0.18$3.99 billion$3.89 billion
3/10/2025Q4 2024
BioNTech SE stock logo
BNTX
BioNTech
$0.38$1.08+$0.70$1.15$1.24 billion$1.19 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
argenx SE stock logo
ARGX
argenx
N/AN/AN/AN/AN/A
BioNTech SE stock logo
BNTX
BioNTech
$1.531.57%N/AN/A N/A
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
$0.533.63%-8.36%240.91%N/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$1.015.58%N/AN/A N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenx SE stock logo
ARGX
argenx
N/A
8.53
7.88
BioNTech SE stock logo
BNTX
BioNTech
0.01
7.33
7.21
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
0.63
1.31
0.72
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.97
0.98
0.75

Institutional Ownership

CompanyInstitutional Ownership
argenx SE stock logo
ARGX
argenx
60.32%
BioNTech SE stock logo
BNTX
BioNTech
15.52%
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
9.17%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
54.05%

Insider Ownership

CompanyInsider Ownership
argenx SE stock logo
ARGX
argenx
2.43%
BioNTech SE stock logo
BNTX
BioNTech
19.20%
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
0.04%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
0.55%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenx SE stock logo
ARGX
argenx
65061.06 million59.29 millionOptionable
BioNTech SE stock logo
BNTX
BioNTech
3,080240.39 million193.71 millionOptionable
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
47,3003.18 billion3.18 billionOptionable
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
36,8001.13 billion1.13 billionOptionable

Recent News About These Companies

FDA fast-tracks Teva's coeliac disease treatment
Teva initiated with bullish view at Truist, here's why
Why Is Teva Stock Trading Higher On Tuesday?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
argenx stock logo

argenx NASDAQ:ARGX

$576.24 -3.53 (-0.61%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$574.97 -1.27 (-0.22%)
As of 06:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BioNTech stock logo

BioNTech NASDAQ:BNTX

$97.53 -1.02 (-1.04%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$98.30 +0.77 (+0.79%)
As of 05:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Takeda Pharmaceutical stock logo

Takeda Pharmaceutical NYSE:TAK

$14.59 -0.08 (-0.55%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$14.58 -0.02 (-0.10%)
As of 05/28/2025 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$18.13 +0.42 (+2.37%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$18.23 +0.10 (+0.54%)
As of 06:45 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.